In September 2023, the FDA effectively banned compounding pharmacies from preparing BPC-157 — one of the most popular “healing peptides” sold at longevity and wellness clinics — citing significant safety risks and insufficient data. In April 2026, the FDA reversed that restriction. In July 2026, its own advisory committee recommended formally approving it for compounding. As of this writing, that approval still hasn’t happened, and the compound sits in a genuine legal gray zone: no longer explicitly prohibited, not yet affirmatively cleared.
Almost nothing about the actual human evidence changed during that entire back-and-forth. There is still no completed, published clinical trial in humans showing BPC-157 does what it’s marketed to do. The first real one — a properly randomized, placebo-controlled study — only started recruiting participants in February 2026.
That gap between “the legal status just changed dramatically” and “the evidence didn’t change at all” is the whole story most articles about peptide therapy miss, and it’s exactly the kind of thing ScanGlean exists to untangle. This is a plain-language walk through what’s actually legal right now, what human evidence exists for the peptides longevity clinics sell most, and what it costs to find out for yourself.
Key takeaways
- The FDA placed BPC-157 and 18 other peptides on its restricted “Category 2” compounding list in September 2023. On April 15, 2026, it removed 12 of them from that list — but removal isn’t approval, and as of late July 2026 the FDA’s own advisory committee was still just recommending formal clearance, not confirming it.
- A 2025 peer-reviewed review in Pharmaceuticals found no completed human clinical trials on BPC-157’s efficacy; a 2015 safety trial’s results were never published, and the first randomized, controlled human trial only began recruiting in February 2026.
- Only one longevity-adjacent peptide, tesamorelin, has real FDA approval — and only for a narrow indication (HIV-associated lipodystrophy), not general anti-aging.
- BPC-157 has been on the World Anti-Doping Agency’s banned list since 2022; a 19-year-old American speed skater was suspended for a year in 2024 after testing positive for it.
- A single peptide protocol at a longevity clinic typically runs $700 to $3,500 all-in, for compounds with little to no controlled human evidence behind them.
The Two Questions That Actually Matter, Kept Separate
Most confusion about peptide therapy comes from conflating two completely different questions. Keep them apart and the topic gets much clearer:
- Is it legal to obtain right now? This changes based on FDA compounding rules and shifts fast — as the 2023-to-2026 timeline below shows.
- Does it work, based on controlled human evidence? This barely changes at all, because generating real clinical evidence takes years, regardless of what the compounding rules say in any given month.
A peptide can move from “restricted” to “gray zone” to eventually “approved for compounding” without a single new human trial being completed in between. Legal status and evidence quality are not the same axis, and longevity clinics marketing these compounds rarely make that distinction for you.
Before spending money on an unproven peptide protocol, see what's already guideline-recommended for your age and risk profile. Answer a few quick, non-identifying questions and get personalized eligibility guidance across all 6 categories ScanGlean covers. Take the Fit Check →
What These Peptides Actually Are
“Peptide therapy” at a longevity clinic usually means one of three different categories, each with a different evidence profile:
- Tissue-repair peptides — BPC-157 and TB-500 are the best-known, marketed for tendon healing, gut repair, and general recovery, based almost entirely on animal studies.
- Growth-hormone secretagogues — CJC-1295, ipamorelin, sermorelin, and tesamorelin, which stimulate the pituitary gland to release more of the body’s own growth hormone rather than supplying growth hormone directly.
- “Longevity” peptides — a newer, more speculative category including epitalon, MOTS-c, and GHK-Cu, marketed around cellular aging and mitochondrial function with the least human data of the three groups.
Lumping all of these together as “peptides” — the way most marketing does — obscures a real difference: some of these compounds have decades of legitimate pharmaceutical history behind a relative in their class (growth-hormone secretagogues), while others are recent research compounds with essentially zero regulatory track record.
The Regulatory Rollercoaster, in Order
This is the part almost no consumer-facing article gets right, because the timeline moved fast and most clinic-run blogs have an obvious incentive to describe the current moment as “now legal.”
| Date | What happened |
|---|---|
| September 2023 | FDA places BPC-157 and 18 other peptides (including TB-500, epitalon, MOTS-c, GHK-Cu, melanotan II, semax, KPV, DSIP, LL-37, dihexa) on Category 2 of its interim 503A bulks list, citing significant safety risks or insufficient data — barring licensed compounding pharmacies from preparing them. |
| 2022 (before the FDA action) | The World Anti-Doping Agency separately adds BPC-157 to its Prohibited List under the S0 Unapproved Substances category. |
| February 27, 2026 | HHS Secretary Robert F. Kennedy Jr. publicly states the FDA will move roughly 14 of the 19 restricted peptides back toward Category 1, citing pressure to loosen compounding restrictions. |
| April 15–16, 2026 | The FDA formally announces the removal of 12 peptides — including BPC-157, TB-500, MOTS-c, GHK-Cu, melanotan II, semax, epitalon, and KPV — from Category 2, effective April 23, 2026. The peptides’ safety nominations were withdrawn rather than formally cleared. |
| July 23–24, 2026 | The FDA’s Pharmacy Compounding Advisory Committee (PCAC) meets and recommends adding BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax to the official 503A Bulk Drugs List — a recommendation, not a final decision. |
| As of this writing | The FDA has not issued a final rule formally approving these peptides for compounding. They remain in a gray zone: not on the restricted list, not on the approved list either. |
The practical effect: a compounding pharmacy today can legally prepare BPC-157 without violating the specific 2023 restriction, but that’s a different thing from the FDA having reviewed and approved it the way it reviews an actual drug. “No longer banned” and “approved” are being used almost interchangeably in a lot of clinic marketing right now, and they mean genuinely different things.
What Human Evidence Actually Exists, Peptide by Peptide
BPC-157
The most rigorous look at this compound is a 2025 review published in Pharmaceuticals by Józwiak and colleagues, which searched the literature and patent filings for every human study on BPC-157 that exists. Their conclusion: there are no completed clinical studies describing its efficacy in humans. A Phase I safety trial enrolling 42 healthy volunteers was registered in 2015 — but the researchers cancelled submission of the results in 2016, and nothing was ever published. The only human data that exists consists of a handful of tiny, uncontrolled reports: a retrospective case series of 12 knee-pain patients (the authors themselves note the results “are not overly informative and reliable,” since there was no standardized tool to measure improvement) and a 2025 pilot safety study giving intravenous BPC-157 to two healthy adults. In February 2026, a company called Hudson Biotech began recruiting for what appears to be the first randomized, placebo-controlled human trial of BPC-157 — meaning, as of today, real evidence generation is just getting started, years after clinics began selling it.
CJC-1295 and Ipamorelin
These growth-hormone secretagogues work by stimulating the pituitary gland rather than delivering growth hormone directly, which gives them a somewhat more established pharmacological basis than BPC-157. They’re most often used off-label for documented age-related growth hormone decline. The theoretical safety concern raised in the literature is shared across this entire drug class: anything that stimulates broader cell growth carries a theoretical cancer-risk signal, which is part of why growth-hormone-axis drugs require monitoring rather than being treated as low-risk wellness additives.
Tesamorelin
This is the one real exception in the category. Tesamorelin (Egrifta) received full FDA approval in November 2010 for a specific, narrow indication: reducing excess abdominal fat in HIV-positive adults with lipodystrophy. It remains the only growth-hormone-releasing peptide with active FDA approval. When a longevity clinic prescribes it for general anti-aging or fat loss in someone without that condition, that’s a legal off-label use of an approved medication — a fundamentally different, more evidence-backed situation than prescribing a compounded, never-approved research compound, even though both might appear on the same clinic’s peptide menu.
Sermorelin
Sermorelin’s branded version (Geref) was approved for pediatric growth hormone deficiency but was voluntarily discontinued by its manufacturer in 2008 for commercial reasons, not safety ones. It’s now available only through compounding pharmacies for individual prescriptions, occupying a middle ground: it has real prior FDA approval history, just not an active one today.
The Real-World Stakes: This Isn’t Hypothetical
BPC-157 has been on the World Anti-Doping Agency’s Prohibited List since 2022, under the category for substances with no approved therapeutic use anywhere in the world — which by definition means no therapeutic use exemption is available for it. In 2024, a 19-year-old American speed skater was suspended for a year after testing positive for a product containing BPC-157. For competitive athletes specifically, “my longevity clinic prescribed it” offers no protection, because the substance isn’t recognized as a legitimate therapeutic anywhere in the first place.
For non-athletes, the more relevant risk is simpler: sourcing. Because many of these compounds are marketed and sold as “research chemicals” to sidestep pharmaceutical regulation entirely, purity, correct dosing, and contaminant levels vary enormously between providers, and there’s no equivalent of standard drug manufacturing oversight verifying what’s actually in the vial.
What It Actually Costs
Pricing varies by clinic and by which peptide or stack you’re getting, but the ranges are fairly consistent across providers:
| Item | Typical cost |
|---|---|
| Single peptide (e.g., BPC-157) | $150–$450/month |
| CJC-1295 + ipamorelin combination | $250–$450/month |
| Full 8–12 week protocol (peptide only) | $450–$2,700 |
| Initial consultation + baseline labs | $150–$500 |
| Follow-up visit | $75–$200 |
| Typical all-in cost per protocol | $700–$3,500 |
Physician-scientist Eric Topol, whose critique of longevity-marketing companies is cited elsewhere on this site, has specifically flagged the pricing-versus-evidence gap in peptide therapy: monthly costs in the hundreds of dollars, and membership fees at some clinics reaching into the tens of thousands annually, for compounds where — as he puts it — “there is no evidence from randomized trials in humans that any of these peptides provide the benefits that are advocated.”
Questions Worth Asking Before You Start
- Which specific peptide, exactly, and what’s the actual human evidence for it — not preclinical animal data, not testimonials, but published human trial data. For most of these compounds, the honest answer right now is “very little to none.”
- Is this a compounded substance in the current regulatory gray zone, or an FDA-approved drug being used off-label? Those are different risk categories, even when they’re sold from the same clinic menu.
- Where is it actually sourced from, and can the clinic show pharmaceutical-grade sourcing and testing documentation, rather than “research chemical” supply chains?
- What monitoring is included — baseline and follow-up labs to catch the theoretical risks (like cancer-risk signals tied to growth-stimulating compounds) that the scientific literature flags?
- What would change your mind about continuing it — is there a defined endpoint or outcome you’re tracking, or is this an indefinite, ongoing subscription?
The Bottom Line
The legal status of peptides like BPC-157 has changed dramatically since 2023 — banned, then unbanned, then recommended (but not yet confirmed) for formal approval, all within about three years. The human evidence behind most of these compounds has barely moved at all during that same period, because real clinical trials take years to design, run, and publish, regardless of what compounding rules say in any given month. A regulatory reversal is not the same thing as new proof that something works. If a longevity clinic’s marketing conflates the two, that’s worth noticing — and worth asking about directly before you pay for a protocol built on animal data and a Phase I trial whose results were never published.
Frequently Asked Questions
Is BPC-157 legal in 2026?
It’s in a genuine regulatory gray zone, not a clear yes or no. The FDA placed BPC-157 on its Category 2 restricted compounding list in September 2023, citing safety and data concerns. On April 15, 2026, the FDA removed BPC-157 and 11 other peptides from Category 2 after their safety nominations were withdrawn — but removal from the restricted list is not the same as approval. As of this writing, the FDA’s own Pharmacy Compounding Advisory Committee only recommended in late July 2026 that BPC-157 be added to the approved 503A Bulk Drugs List, and the FDA has not yet made a final decision. Compounding pharmacies exist in an ambiguous middle zone right now: no longer explicitly prohibited, not yet affirmatively authorized.
Is there human clinical trial evidence for BPC-157?
Almost none. A 2025 comprehensive literature review published in the journal Pharmaceuticals found no completed clinical trials describing BPC-157’s efficacy in humans. A 2015 Phase I safety trial enrolling 42 healthy volunteers had its results submission cancelled in 2016 and was never published. Only a small number of tiny, uncontrolled studies exist, including a 12-patient retrospective knee-pain case series and a 2-person intravenous safety pilot. The first properly designed randomized, placebo-controlled human trial of BPC-157 began recruiting participants in February 2026 — meaning real evidence is only now starting to be generated, after years of clinics selling it.
Are any longevity peptides actually FDA-approved?
One is, narrowly. Tesamorelin (brand name Egrifta) is the only growth-hormone-releasing peptide with active FDA approval, granted in November 2010 specifically for reducing excess abdominal fat in HIV-positive adults with lipodystrophy — not for general anti-aging, muscle building, or longevity in healthy adults. When a longevity clinic prescribes tesamorelin for those purposes, it’s a legal off-label use of an approved drug, which is a meaningfully different (and generally better-evidenced) situation than compounded, never-approved peptides like BPC-157.
Can peptide use get an athlete banned from competition?
Yes. The World Anti-Doping Agency added BPC-157 to its Prohibited List in 2022 under the S0 Unapproved Substances category, and it’s banned year-round under USADA and every other national anti-doping body that follows the WADA code. In 2024, a 19-year-old American speed skater received a one-year suspension after testing positive for a product containing BPC-157. There is no therapeutic use exemption available for it, because it isn’t an approved therapeutic agent anywhere.
How much does peptide therapy cost at a longevity clinic?
Typically $150 to $450 per month for a single peptide like BPC-157 or a CJC-1295/ipamorelin combination, with a full 8-to-12-week protocol running roughly $450 to $2,700 depending on what’s included. Most clinics add separate charges for the initial consultation and baseline lab panel ($150–$500) plus follow-up visits ($75–$200 each), so the all-in cost of a single protocol commonly lands between $700 and $3,500.
What are the safety risks of unregulated peptides?
The core risk is that almost nothing about them has been formally verified: purity, correct dosing, contaminant levels, and long-term effects in humans are all largely unknown outside of animal data. Specific theoretical concerns raised in the scientific literature include angiogenesis-related tumor growth risk with BPC-157, and broader cancer-risk theory associated with growth-hormone-stimulating peptides generally, since anything that promotes cell growth carries that risk in principle. Because many of these products are sourced as “research chemicals” rather than pharmaceutical-grade compounds, sourcing and quality control vary enormously between providers.
Why do so many longevity clinics offer peptide therapy if the evidence is this thin?
Because the regulatory ambiguity, genuine (if very early) preclinical promise, and strong word-of-mouth/influencer marketing have created real consumer demand, and peptides are a recurring, relatively low-overhead revenue stream compared to imaging equipment or genomic sequencing. Physician-scientist Eric Topol has written that longevity and wellness companies pushing these compounds “have not yet provided any evidence for benefit” in controlled human studies, and that the current boom reflects demand and marketing more than an evidence base.
Should I try peptide therapy for longevity or anti-aging?
That’s a decision between you and a physician who knows your full medical history — this article isn’t telling you to start or avoid it. What’s worth knowing before that conversation: which specific peptide you’re being offered, whether it has any human trial data at all (most don’t), whether it’s a compounded substance in the current regulatory gray zone versus an FDA-approved drug used off-label, and where the clinic is actually sourcing it from.
This article is for general educational and informational purposes only. It is not medical advice, and it is not a substitute for diagnosis, treatment, or guidance from a licensed physician or other qualified healthcare provider. Regulatory status described in this article reflects our research as of early August 2026 and may change — always verify current FDA compounding status before making a decision, and consult a clinician before starting or stopping any treatment. See our Methodology page for how we research and grade the evidence behind claims like these.
Sources
- Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel), 2025.
- U.S. Food and Drug Administration. Interim 503A Bulks List, Category 2 placements and removals, 2023–2026.
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) meeting proceedings, July 23–24, 2026.
- U.S. Food and Drug Administration. Egrifta (tesamorelin) approval, 2010 — FDA-approved labeling for HIV-associated lipodystrophy.
- World Anti-Doping Agency. The Prohibited List.
- U.S. Anti-Doping Agency. BPC-157: Experimental Peptide Creates Risk for Athletes.
- Topol E. The Peptide Craze. Ground Truths (Substack), 2026.
- Pharmacy Times. The Peptide Reclassification Everyone’s Talking About: A Pharmacist’s Take on What RFK Jr’s Announcement Actually Means, 2026.
- ScanGlean. Fountain Life vs Human Longevity vs Superpower vs Next Health: Longevity Clinics Compared.
- ScanGlean. Rapamycin for Longevity: What the Evidence Actually Shows.